Table 5. Reported frequencies of known polymorphisms and population variants in the CYP1B1, MYOC, OPTN, and OPTC genes in primary open-angle glaucoma patients and controls from different populations.

Gene	Polymorphism/ population variant	Frequency in population			Reference
		POAG (%)	Controls (%)	Population
CYP1B1	C.IVS1-120T	23	22	Eastern India	Acharya etal [20].
	c.I42C>G(Arg48Gly)	43.5	39	Eastern India	Acharya et al. [20]
	c.355G>T(Alall9Ser)	43.5	39	Eastern India	Acharya et al. [20]
	c.729G>C (Val243Val)	1.27	4.26	France	Mclki etal [2].
	c.l294G>C(Val432Leu)	51	59	Eastern India	Acharya et al. [20]
	c.l347T>C(Asp449Asp)	51	60	Eastern India	Acharya et al. [20]
	C.1358A>G (Asn453Ser)	16.5	14	Eastern India	Acharya et al. [20]
MYOC	-83G>A (Promoter region)*	18	23	U.S.A.	Alwardet al [29].
		30	39	Japan	Suzuki et al. [41]
		73.2	68.62	Eastern India	Mukhopadhyy et al. [16]
	c.227G>A (Arg76Lys)	19	18.7	U.S.A.	Alwardet al [29].
		73.2	68.62	Eastern India	Mukhopadhyy et al. [16]
	c.366C>T(Glyl22GIy)	0.53	0.0	U.S.A.	Alwardetal [29].
	c.l041T>C(Tyr347Tyr)	5.4	7.7	U.S.A	Alward et al. [29]
OPTN	c.603T>A (Mel98Lys)	28.6	24.6	China	Leung et al. [36]
		13.6	2.1	U.S.A.	Rezaieetal [13].
		11	5.5	Eastern India	Mukhopadhyay et al. [21]
		4.1	0.0	South Indian state of Tamil Nadu	Sripriya et al. [22]
		16.9	5	Japan	Fuseet al [33].
		6.25	7	Germany	Weisschuh et al. [35]
		4.64	4.54	France	Mclki et al. [39]
		10.7	8.33	Morocco	Melki et. al. [39]
		13.33	13.78	Japan	Toda ct al [37].
		20.7	9.0	Japan	Alwardet al [38].
	c.712C>A (Alal34Ala)	1.75	0.92	Afro-Caribbean Jewish/Scottish/African Somalian	Willoughby et al. [42]
	IVS7+24G>A	10.9	4	China	Leung et al. [36]
OPTC	c.803T>C (Leu268Pro)	6.9	14.55	French-Canada	Friedman ct al [23].
	c.810G>A (Leu270Leu)	0.0	3.66	French-Canada	Friedman ct al [23].

We did not look for another MYOC promoter polymorphism at nt -1000 (-1000C>G; MYOC.mt1; asterisk) in our primary open-angle glaucoma (POAG) data set because Alward et al. [43] and Özgül et al. [44] have observed that it is not a risk factor for the development of glaucoma in patients from the U.S.A. or Turkey, respectively.